ALK sets sights on 2014 dust mite allergy filing
This article was originally published in Scrip
Executive Summary
ALK is planning a 2014 European filing for its allergy immunotherapy tablet treatment for house dust mite allergy, following the success of its first Phase III trial, and presuming that a second study due to report by the end of the year also proves positive.